Norwich Pharmaceuticals has failed to get around an unfavorable US patent-infringement ruling over Bausch Health’s Xifaxan (rifaximin) by filing an amended ‘skinny label’ abbreviated new drug application with patent protected indications carved from the label.
US Court Shoots Down Norwich In ‘Unprecedented’ Xifaxan ‘Skinny Label’ Claim
Delaware Court ‘Hesitant To Be The First’ To Allow Relief Claim To Proceed
Coming down heavily on Norwich Pharmaceuticals, a US district court has denied the US-based generics firm’s bid for relief post-judgment in a case involving the “hotly disputed” issue of skinny label ANDA products.
More from Legal & IP
More from Generics Bulletin
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
• By
Generics Bulletin previews the most noteworthy and anticipated events for April 2025.